Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma

Drug resistance remains the key problem in cancer treatment. It is now accepted that each myeloma patient harbors multiple subclones and subclone dominance may change over time. The coexistence of multiple subclones with high or low chromosomal instability (CIN) signature causes heterogeneity and dr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Invest
Autors principals: Franqui-Machin, Reinaldo, Hao, Mu, Bai, Hua, Gu, Zhimin, Zhan, Xin, Habelhah, Hasem, Jethava, Yogesh, Qiu, Lugui, Frech, Ivana, Tricot, Guido, Zhan, Fenghuang
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6026005/
https://ncbi.nlm.nih.gov/pubmed/29863498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI98765
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars